Beginner Gains Stack –
LGD4033 + RAD140

Research Compound Bundle | Dual SARM Formulation

The Beginner Gains Stack by Vi Corpus combines two investigational selective androgen receptor modulators (SARMs): LGD-4033 (Ligandrol) and RAD-140 (Testolone).

Both compounds have been investigated for their interactions with androgen receptors, with scientific research exploring receptor selectivity, tissue-specific pharmacological activity, androgen-mediated signalling pathways and pharmacokinetic characteristics.

This two-bottle research bundle provides each compound separately in a 30 mL liquid formulation, with individual concentrations and specifications clearly identified.

What's Included

Compound	Concentration	Bottle Size	Quantity
LGD-4033 (Ligandrol) – Extreme Physique	10 mg/mL	30 mL	1 bottle
RAD-140 (Testolone)	15 mg/mL	30 mL	1 bottle

Total Package: 2 × 30 mL bottles (60 mL).

Compound Information

LGD-4033 (Ligandrol) – Extreme Physique

LGD-4033, also known as Ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator (SARM).

LGD-4033 has been studied for its interaction with androgen receptors, particularly in research involving skeletal muscle physiology, bone-related biological processes and androgen receptor-mediated signalling.

Scientific investigations have examined its receptor selectivity, pharmacokinetic behaviour and endocrine responses. These findings contribute to the scientific understanding of nonsteroidal androgen receptor modulators.

Key Research Areas:

• Selective androgen receptor binding and activation
• Skeletal muscle and bone-related signalling pathways
• Tissue-specific androgen receptor activity
• Pharmacokinetic and metabolic characteristics
• Endocrine and hormonal feedback mechanisms

RAD-140 (Testolone)

RAD-140, also known as Testolone or Vosilasarm, is an investigational nonsteroidal selective androgen receptor modulator (SARM).

RAD-140 has been investigated for its selective interactions with androgen receptors and its pharmacological activity in androgen-responsive tissues.

Unlike testosterone and conventional anabolic androgenic steroids, RAD-140 has a nonsteroidal chemical structure. Research has examined its receptor-binding characteristics, tissue-selective activity and pharmacokinetic properties.

Key Research Areas:

• Selective androgen receptor binding and activation
• Androgen receptor signalling pathways
• Tissue-selective pharmacological characteristics
• Nonsteroidal androgen receptor modulation
• Pharmacokinetic and metabolic properties

Product Specifications

Specification	Details
Product Name	Beginner Gains Stack
Brand	Vi Corpus
Compound 1	LGD-4033 (Ligandrol / VK5211)
Compound 2	RAD-140 (Testolone / Vosilasarm)
Compound Classification	Selective Androgen Receptor Modulators (SARMs)
LGD-4033 CAS Number	1165910-22-4
RAD-140 CAS Number	1182367-47-0
LGD-4033 Concentration	10 mg/mL
RAD-140 Concentration	15 mg/mL
Form	Liquid formulations
Bottle Size	30 mL each
Total Bottles	2
Total Volume	60 mL
Intended Purpose	Laboratory research only

Research and Scientific Background

LGD-4033 and RAD-140 are nonsteroidal selective androgen receptor modulators investigated for their ability to interact with androgen receptors.

Although both compounds share a common receptor target, they differ in chemical structure, pharmacological characteristics and the extent of available scientific research.

Studies involving selective androgen receptor modulators have examined their interactions with skeletal muscle and bone-related pathways, tissue selectivity and endocrine feedback mechanisms.

However, findings from research involving either compound individually do not establish the safety or effectiveness of combining LGD-4033 and RAD-140.

Important Research Disclaimer

LGD-4033 and RAD-140 are investigational selective androgen receptor modulators and are not approved for human therapeutic use in Australia.

This information is intended for scientific and technical reference purposes only. It does not constitute a recommendation for personal administration, bodybuilding cycles, athletic performance enhancement or the treatment of medical conditions.

The safety and efficacy of administering LGD-4033 and RAD-140 together have not been established. Potential risks associated with SARMs include hormonal suppression, liver injury and adverse cardiovascular effects.

No claims are made regarding the safety, efficacy or therapeutic benefits of combining these compounds.